mezagitamab   Click here for help

GtoPdb Ligand ID: 10609

Synonyms: TAK-079 | TAK079
Immunopharmacology Ligand
Compound class: Antibody
Comment: Mezagitamab (TAK-079) is a humanized, IgG1, cell-depleting anti-CD38 monoclonal antibody [3-4]. Anti-CD38 therapeutics were primarily developed as treatments for multiple myeloma [5], but have subsequently been discovered to offer potential in solid tumours and autoimmune diseases [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
CD38 is expressed constitutively by plasma cells and natural killer (NK) cells. Its expression is upregulated on subsets of T and B cells following their activation. TAK-079 binds human and cynomolgus monkey CD38, which is in contrast to daratumumab and isatuximab which do not cross‐react with monkey CD38. It exhibits no agonist activity at CD38, and effectively depletes subsets of NK, B, and T cells in monkeys.